1. Home
  2. NGNE vs ASG Comparison

NGNE vs ASG Comparison

Compare NGNE & ASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$27.00

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

ASG

Liberty All-Star Growth Fund Inc.

HOLD

Current Price

$5.23

Market Cap

328.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
ASG
Founded
2003
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
327.8M
328.8M
IPO Year
2014
1995

Fundamental Metrics

Financial Performance
Metric
NGNE
ASG
Price
$27.00
$5.23
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$63.57
N/A
AVG Volume (30 Days)
138.7K
270.1K
Earning Date
05-08-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
0.93
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.78
$4.55
52 Week High
$37.27
$5.69

Technical Indicators

Market Signals
Indicator
NGNE
ASG
Relative Strength Index (RSI) 64.63 59.85
Support Level $19.40 $5.04
Resistance Level $29.05 $5.27
Average True Range (ATR) 1.86 0.07
MACD 0.53 0.02
Stochastic Oscillator 78.73 93.29

Price Performance

Historical Comparison
NGNE
ASG

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About ASG Liberty All-Star Growth Fund Inc.

Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company's portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.

Share on Social Networks: